Skip to content

Application of RVS in sub-segment-based anatomical hepatectomy for primary liver cancer

Application of RVS in sub-segment-based anatomical hepatectomy for primary liver cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055585
Enrollment
Unknown
Registered
2022-01-14
Start date
2020-05-01
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

experimental group:RVS with ICG
control group:ICG

Sponsors

Peking University International Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 20-75 years old, gender is not limited; 2. No obvious organic lesions of heart, lung, kidney, brain and other important organs; 3. Preoperative evaluation of liver function: Child-Pugh A or B, according to Makuuchi According to the M standard, quantitative anatomical liver resection with sub-segmentation as the main method can be evaluated; 4. No radiotherapy, chemotherapy or interventional treatment for the HCC has been performed within 4 weeks before surgery; 5. Preoperative imaging examination and No tumor thrombus was found in the trunk and branches of the portal vein, the main hepatic duct and branches, the trunk and branches of the hepatic vein, and the inferior vena cava by intraoperative ultrasound; 6. No extrahepatic invasion and metastasis were found during the operation; 7. Voluntary subjects, and Those who signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who have received radiotherapy, chemotherapy and interventional therapy for the HCC within 4 weeks before surgery; 2. Those who are allergic to ICG or iodine; 3. The main and branches of the portal vein, the common hepatic duct and Branches, main hepatic veins, branches and inferior vena cava with tumor thrombus; 4. Extrahepatic invasion and metastasis were found during operation.

Design outcomes

Primary

MeasureTime frame
tumor recurrence time;

Countries

China

Contacts

Public ContactKeming Zhang
zhangkeming@pkuih.edu.cn+86 13910458576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026